Epilepsy & Seizures
Photosensitive occipital lobe epilepsy
Dec. 03, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Lafora disease …
- Updated 05.31.2024
- Released 04.26.1995
- Expires For CME 05.31.2027
Lafora disease
Introduction
Overview
Lafora disease is a severe form of progressive myoclonus epilepsy characterized by the onset of seizures or cognitive decline during late childhood or adolescence with a progressive course, usually ending in death 5 to 10 years after the initial symptoms. Lafora disease is caused by mutations in the EPM2A or EPM2B/NHLRC1 genes, encoding the laforin phosphatase and the malin ubiquitin ligase, respectively, two cytoplasmically active enzymes that regulate glycogen construction. Pathologically, the disease is characterized by the presence of polyglucosan intracellular inclusion bodies called Lafora bodies in neurons and other tissues. Despite improved patient diagnosis, prenatal diagnosis, and genetic counseling for this devastating disease, treatment is primarily palliative, aiming at seizure reduction. In this article, the author summarizes the clinical manifestations and rapidly expanding information on the genetic basis and metabolic derangements of Lafora disease and some promising results from the treatment of animal models.
Key points
|
• Lafora disease is an autosomal recessive progressive myoclonus epilepsy characterized by the accumulation of insoluble abnormal glycogen deposits in the brain and peripheral tissues. Clinically it manifests with cortical myoclonus, other types of epileptic seizures, progressive intellectual decline, ataxia, and early death. | |
|
• Onset of symptoms is in the second decade of life, typically between the ages of 11 and 18 years. Death usually occurs 2 to 10 years after onset (mean 5 years). | |
|
• The pathological hallmark of Lafora disease is the presence of cytoplasmic polyglucosan inclusions, the Lafora bodies. | |
|
• The disease is caused by mutations in either the EPM2A gene, encoding the protein phosphatase laforin, or the EPM2B gene, encoding the ubiquitin ligase malin. | |
|
• The MRI shows subtle or no abnormalities, and the EEG is grossly abnormal even in early stages. Biopsy or genetic studies are required for a definitive diagnosis. | |
|
• Management is only supportive and palliative, limited to symptomatic management of the epileptic seizures, myoclonus, and intercurrent complications. There are promising therapies in development in preclinical stages that soon may proceed to clinical trials. |
Historical note and terminology
The neuropathological features typically found in Lafora disease were first described by Gonzalo Rodríguez Lafora in 1911 (39; 39).
It was soon established that the presence of typical Lafora inclusion bodies in the pathological material was associated with a progressive neurologic disorder with myoclonus, different types of seizures, and dementia. This triad of symptoms characterizes a group of diseases categorized as progressive myoclonic epilepsies (07; 29; 61; 50). Lafora disease is recognized as one of the major causes of progressive myoclonus epilepsy with well-defined clinical and pathological characteristics. In 2021, the Commission on the Classification and Terminology of the International League Against Epilepsy (ILAE) classified Lafora disease in the group of epilepsy syndromes with developmental and/or epileptic encephalopathy, or with progressive neurologic deterioration (55).
Clinical manifestations
Presentation and course
Lafora disease is characterized by symptoms common to the other progressive myoclonus epilepsies: severe myoclonus, major generalized convulsive seizures, and dementia (07; 29; 61; 30; 47; 50; 66; 36). Focal occipital seizures occur in about half of the patients.
Onset of symptoms is in the second decade of life, typically between the ages of 11 and 18 years.
A few cases of the adult-onset form of the disease have been described in patients with typical Lafora inclusion bodies and a more benign course (37; 64). Slowly progressive forms are most commonly due to EPM2B mutations (32). Also, an early-onset form of Lafora disease with dyslexia and learning disorder followed by epilepsy and neurologic deterioration has been described (25). This form is associated mainly with mutations in exon 1.
The natural course of Lafora disease can be divided into three phases (16). Initially, most cases start with convulsive tonic-clonic seizures and myoclonic jerks, and some cases can mimic juvenile myoclonic epilepsy; the jerks are massive and synchronous bilateral myoclonic jerks of brief duration, usually limited to one or more muscle groups. The myoclonic jerks are not associated with loss of consciousness and are usually triggered by visual stimulation or proprioceptive impulses (07; 29; 61; 30; 47; 50). Epileptic visual seizures with elementary visual hallucinations may be an early sign of the disease. Behavioral changes or decline of school performance (34), hepatic disease (33), and, occasionally, parkinsonism (54) may also be the starting symptoms.
With progression, myoclonus increases in intensity and becomes severe and multifocal, precipitated by posture or action. At this point, intellectual deterioration occurs rapidly. An advanced stage characterized by severe dementia, spastic quadriparesis, and almost constant myoclonic seizures and frequent generalized tonic-clonic seizures is reached within 2 to 10 years after the onset of symptoms in classic Lafora disease.
Prognosis and complications
Lafora disease has a poor prognosis. In the final stages, severe dementia is always a major feature. Death usually occurs 2 to 10 years after onset (mean 5 years). The mean age at death is 20 years (29).
A milder phenotype has been described in those with NHLRC1 mutations, where a later age of onset, slower disease progression, and longer life expectancy was observed (23; 12). However, a “mild” or slowly progressive course may also be seen in patients with EPM2A mutation (personal observation).
Clinical vignette
A 19-year-old girl started at age 14 years with myoclonic jerks followed early in the evolution by generalized tonic-clonic seizures and elementary visual hallucinations. She was misdiagnosed with juvenile myoclonic epilepsy and started on antiepileptic drugs without achieving seizure control. One year later, she developed gait unsteadiness and cognitive and speech impairment causing school failure. Her neurologist suspected a progressive myoclonus epilepsy, and the genetic test revealed a homozygous mutation in EPM2B. At age 19 years, she had almost continuous myoclonus, severe cognitive deterioration, and frequent generalized tonic-clonic and myoclonic seizures despite having tried different antiepileptic drugs. The EEG showed a slow and disorganized background activity with very frequent polyspike and spike-waves discharges that decreased during sleep.
Biological basis
Etiology and pathogenesis
The pathologic picture of Lafora disease is unique (39). PAS-positive inclusions (Lafora bodies) are present throughout the nervous system, particularly in the dentate nucleus, red nucleus, substantia nigra, and hippocampus. Lafora bodies are also seen in various tissues, including liver, skeletal and cardiac muscle, and skin (14). The inclusions consist largely of polyglucosans that are poorly branched and insoluble forms of glycogen, highly phosphorylated and with small variable sulfate groups (57; 14; 67). Lafora bodies occupy vast numbers of neuronal dendrites and perikarya in Lafora disease in time-dependent fashion, leading to intractable and fatal progressive myoclonus epilepsy. Studies of different tissues have revealed that the storage material has some histochemical and morphological differences, varying from organ to organ. Lafora bodies, as seen by electron microscopy, appear to be free in the cytoplasm of neurons and in eccrine sweat-gland duct cells. In hepatic cells, the storage material displaces various organelles to the periphery, and the center of the cytoplasm is occupied by hypertrophic smooth endoplasmic reticulum containing the PAS-positive material. In skeletal muscle, the inclusions are definitively surrounded by membranes (66).
Lafora disease is an autosomal recessive disorder caused by loss-of-function mutations in the EPM2A/NHLRC1 gene, which encodes a protein tyrosine phosphatase (laforin), or in the EPM2B gene, which encodes an E3 ubiquitin ligase (malin) that ubiquitinates and promotes the degradation of laforin (45). It is characterized by the presence of abnormally branched water-insoluble glycogen inclusions known as Lafora bodies in the neurons and other tissues (60; 15; 35; 26; 28; 42; 18; 63; 62; 30; 47; 38; 66; 49; 51; 36; 10). Laforin's principal function is to control glycogen chain lengths in a malin-dependent fashion, and loss of this control underlies Lafora disease. Mouse models of Lafora disease, developed by targeted disruption of the EPM2A or EPM2B genes, recapitulated most of the symptoms and pathological features as seen in humans and offered insight into the pathomechanisms (27). Evidence from these models indicates that Lafora bodies are a principal driver of neurodegeneration and neurologic disease.
Over 100 distinct mutations in EPM2A or EPM2B/NHLRC1 have been discovered in over 200 independent families affected by Lafora disease; nearly half of them are missense mutations, one quarter are deletion mutations (62), and novel mutations are common (41; 19; 59; 24; 02; 56). In a homogeneous environment and gene pool, the same Lafora epilepsy mutation resulted in highly uniform ages of onset (14 years) and death (21 years) (65).
Experimental work has shown that glycogen synthesis is requisite for Lafora body formation and that Lafora bodies are pathogenic. Elimination of brain glycogen synthesis in Lafora disease mice prevents Lafora body formation, neurodegeneration, and seizure susceptibility (52; 20).
The myoclonus of Lafora disease is epileptic cortical myoclonus. However, with progression of the disease, the degenerative process affects both cortical and subcortical structures; therefore, epileptic and nonepileptic myoclonus may coexist.
Cognitive impairment in Lafora disease is predominantly due to metabolic damage in the frontal cortex (53). Areas of decreased glucose metabolism in Lafora disease are extensive, often involving multiple cortical and subcortical regions, with the thalamus and the temporal, frontal, and parietal lobes being the most severely affected (48).
Epidemiology
Lafora disease is an ultra-rare disease and is seen worldwide but is more common in geographic isolates and areas with a high degree of inbreeding. In Western countries, prevalence is estimated to be well below 1 in 1,000,000. The disease probably accounts for 10% of patients with progressive myoclonus epilepsy. In one study, 12 of 84 (14.2%) patients with progressive myoclonic epilepsy had Lafora disease (04).
Lafora disease is a frequent cause of progressive myoclonus epilepsy in populations of Mediterranean origin, whereas it is rare or absent in Scandinavian countries, particularly Finland, where Unverricht-Lundborg disease is the predominant form. A cluster of families has been described in the south of India (01). There are several reports of cases in Japan (69) and China, and a few cases have been reported in Great Britain (21).
Prevention
Due to its genetic nature, genetic counseling should be offered to families with confirmed cases of the disorder (36). No environmental factors are believed to play a role in causing the disease.
Prenatal testing. If EPM2A or EPM2B pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be offered.
Preimplantation genetic diagnosis. This may be an option for some parents in whom EPM2A or EPM2B pathogenic variants have been identified.
Differential diagnosis
Recognition of Lafora disease in its fully developed form is not difficult, though in its initial stages the disease can resemble juvenile myoclonic epilepsy or occipital epilepsy. The presence of: (1) tonic-clonic and focal visual seizures to bilateral tonic-clonic seizures, followed by myoclonic jerks (not exclusively on awakening), associated with myoclonus that is more often postural and triggered by movements; (2) EEG background slowing with superimposed diffuse epileptiform abnormalities with occipital epileptiform discharges; and (3) drug-resistant epilepsy and cognitive impairment during the evolution of the disease gives rise to the suspicion of a progressive disease, such as Lafora disease (17).
Another important distinction has to be made from the other major causes of progressive myoclonic epilepsy: a hallmark of this group of epilepsies is progressive myoclonus that is triggered by action, is multifocal, and becomes refractory (12). The group of progressive myoclonic epilepsies include Unverricht-Lundborg disease, neuronal ceroid lipofuscinosis, sialidosis, and mitochondrial encephalomyopathy (06; 29; 50). Rare causes of progressive myoclonus epilepsy include dentatorubral-pallidoluysian atrophy, noninfantile neuronopathic Gaucher disease, late-infantile and juvenile forms of GM2 gangliosidosis, the juvenile form of neuroaxonal dystrophy, Hallervorden-Spatz syndrome, and action myoclonus-renal failure syndrome. Most of the above disorders can be differentiated from Lafora disease by their typical ages at onset of symptoms and by the absence of Lafora bodies. The presence of the typical pathological findings is important in patients in whom the disease presents as a predominantly dementing illness with relatively infrequent seizures or when it mimics nonspecific secondary generalized epilepsy with mild myoclonus. Nonepileptic myoclonus disorders can also be differentiated based on clinical and pathological characteristics.
Diagnostic workup
The EEG shows progressive slowing of the background rhythm and generalized epileptiform discharges. Focal or multifocal, often posterior, epileptiform abnormalities are also seen. Photosensitivity is common. Mid and even early stages of the disease can reveal a grossly abnormal recording with severe slowing and very frequent epileptiform discharges that may almost disappear during sleep. EEG patterns through the disease course can also change. At onset of epilepsy, the EEG may only show findings of a generalized genetic epilepsy, which then progresses to slowing of the background, multifocal epileptiform discharges, and occipital abnormalities. In the final stage of the disease, which is characterized by severe dementia and refractory epilepsy, the EEG background may slow further with frequent fast multifocal spikes (16). Neurophysiological study of the myoclonus is consistent with cortical myoclonus (50).
1H-magnetic resonance spectroscopy is more sensitive than structural MRI to detect brain involvement. The greatest metabolic changes are seen in the frontal cortex, cerebellum, and basal ganglia (68). In a study, a statistically significant difference was found between NAA/Cho ratio in the cerebellum in patients with Lafora disease compared with normal controls (P= 0.04) (03). In addition, both myoclonus and ataxia scores showed significant correlation with NAA/Cho ratios in the pons (P= 0.03, P= 0.04) and in the cerebellum (P= 0.04, P= 0.01), respectively (03).
A study by d'Orsi and colleagues looked at biomarkers FDG-PET, CSF Aβ42, CSF p-tau181, and t-tauAg to correlate with severity of disease (16). The group found that in the mid to final stages of the disease, CSF patterns were similar to non-Alzheimer dementia. PET hypometabolism was more often seen in the parietal, precuneus, posterior cingulate, and frontal regions. As the disease progressed, there was involvement of the thalamus and lateral temporal lobes.
The definitive diagnosis of Lafora disease depends on the detection of the characteristic PAS-positive inclusions, but this approach has both false negatives and false positives (42; 22). Skin biopsy of the axilla is best site because of the typical presence of Lafora bodies in the sweat glands and ducts. To offer adequate samples, the skin biopsy should be deep enough to include entire sweat gland ducts and glands. Cryostat sections stained with PAS are best for demonstrating the inclusions. Electron microscopic confirmation is advisable (14).
As the biopsy may be negative due to sampling error, molecular genetic testing of the EPM2A and EPM2B gene is now the diagnostic procedure of choice. Genetic testing results in the finding of mutations in EPM2A or EPM2B.
Management
Management of Lafora disease is only supportive and palliative (30; 47; 50).
Clonazepam and valproate are the main classic antiepileptic drugs with antimyoclonic efficacy. Of the newer antiepileptic drugs, levetiracetam (09) and zonisamide (70) are considered the most effective. Clobazam and phenobarbital are second options. Fast-acting benzodiazepines are used for temporary relief of myoclonus during social events and the treatment of myoclonic status epilepticus.
Lamotrigine may worsen myoclonus. Other contraindicated antiepileptic drugs include carbamazepine, oxcarbazepine, eslicarbazepine acetate, phenytoin, gabapentin, pregabalin, tiagabine, and vigabatrin—all of which often worsen myoclonus.
Perampanel adjunctive therapy appears to confer particular benefit on seizures and myoclonus in Lafora disease (31).
Vagal nerve stimulation improved seizures in a case with Lafora disease (44). The ketogenic diet did not prevent the deterioration in five patients with Lafora disease (13).
A mouse model of Lafora disease (Epm2b-/-) was subjected to different pharmacological interventions aimed to alleviate protein clearance and endoplasmic reticulum stress. Metformin, an AMPK activator, administration decreased the accumulation of Lafora bodies and polyubiquitin protein aggregates, diminished neurodegeneration (neuronal loss and reactive gliosis), and ameliorated neuropsychological tests (08). Burgos and colleagues looked at outcomes of early versus late metformin treatment (after neurologic symptoms appeared) in both mouse models (Epm2a-/- and Epm2b-/-) and human patients (11). In mice, early metformin treatment was associated with significant improvement in time of seizure onset and prevention of cognitive decline. However, this improvement was not seen in the human patients. They found that patients treated with metformin (both early or late) had a slower progression of disease, specifically in preserving speech and multiple activities of daily living. Metformin has been granted orphan drug designation by the United States Food and Drug Administration and the European Medicines Agency and is being used in clinical practice using standard dosing for diabetes management (1000–2000 mg per day).
In a study, fingolimod was administered in a mouse model to target neuroinflammation. The study found that fingolimod decreased reactive astroglial neuroinflammation and T lymphocytes with improved behavioral performance (58).
In a study of EPM2B deletion and wild type mice, cannabidiol showed some improvement in cognitive function but no effect on seizure control (05; 43). In another knockout mice model of EPM2B -/-, propranolol and epigallocatechin gallate (green tea antioxidant extract) showed improvement in some cognitive domains, and propranolol decreased astrogliosis and microgliosis in mice (43; 46).
New approaches to the treatment of Lafora disease have been discussed in the sixth International Lafora Epilepsy workshop. In brief, there are several potential lines of therapy: (1) small molecule inhibitors of glycogen synthase, (2) enzyme therapy to digest Lafora bodies, (3) antisense oligonucleotides (ASOs) to block glycogen synthase, and (4) repurposed drugs such as metformin. Gene therapy replacing laforin or malin is probably the most promising therapeutic modality but is still in its infancy (43).
Special considerations
Pregnancy
Prenatal testing. If EPM2A or EPM2B pathogenic variants have been identified in an affected offspring, prenatal testing may be available for further pregnancies.
Preimplantation genetic diagnosis. This may be an option for some families in which EPM2A or EPM2B pathogenic variants have been identified in the parents in a carrier state.
There is not enough information on the effect of pregnancy on the disorder.
Acknowledgement
This article is dedicated to the memory of C P Panayiotopoulos MD PhD FRCP, in whose previous outstanding version this update is based.
Media
References
- 01
- Acharya JN, Satischandra P, Asha T, Shankar SK. Lafora's disease in South India: a clinical, electrophysiologic and pathologic study. Epilepsia 1993;34:476-87. PMID 8389290
- 02
- Afrantou T, Lagoudaki R, Papadopoulos T, et al. Novel frameshift variant of NHLRC1 gene in compound heterozygosity in an adult Greek patient with Lafora disease. Seizure 2021;86:49-51. PMID 33540374
- 03
- Altindag E, Kara B, Baykan B, et al. MR spectroscopy findings in Lafora disease. J Neuroimaging 2009;19(4):359-65. PMID 19040628
- 04
- Andermann F, Berkovic SF, Carpenter S, Andermann E. The Ramsay Hunt syndrome is no longer a useful diagnostic category. Mov Disord 1989;4:14-7. PMID 2494436
- 05
- Aso E, Andres-Benito P, Grau-Escolano J, et al. Cannabidiol-enriched extract reduced the cognitive impairment but not the epileptic seizures in a Lafora disease animal model. Cannabis Cannabinoid Res 2020;5(2):150-63. PMID 32656347
- 06
- Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986;315:296-305. PMID 3088452
- 07
- Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8:261-74. PMID 1918332
- 08
- Berthier A, Paya M, Garcia-Cabrero AM, et al. Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol Neurobiol 2016;53(2):1296-309. PMID 25627694
- 09
- Boccella P, Striano P, Zara F, et al. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters. Clin Neurol Neurosurg 2003;106:55-9. PMID 14643920
- 10
- Brewer MK, Putaux JL, Rondon A, et al. Polyglucosan body structure in Lafora disease. Carbohydr Polym 2020;240:116260. PMID 32475552
- 11
- Burgos D, Machio-Castello M, Iglesias-Cabeza N, et al. Early treatment with metformin improves neurological outcomes in Lafora disease. Neurotherapeutics 2023;20(1):230-44. PMID 36303102
- 12
- Cameron J, Ellis C, Berkovic S, et al. ILAE genetics literacy series: progressive myoclonus epilepsies. Epileptic Disord 2023;25(5):670-80. PMID 37616028
- 13
- Cardinali S, Canafoglia L, Bertoli S, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res 2006;69:129-34. PMID 16504479
- 14
- Carpenter S, Karpati G. Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. Neurology 1981;31:1564-8. PMID 6796905
- 15
- Chan EM, Andrade DM, Franceschetti S, Minassian B. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv Neurol 2005;95:47-57. PMID 15508913
- 16
- d’Orsi G, Farolfi A, Muccioli L, et al. Association of CSF and PET markers of neurodegeneration with electroclinical progression in Lafora disease. Front Neurol 2023;14:1202971. PMID 37448753
- 17
- d’Orsi G, Lalla A, Palumbo O, et al. The presenting symptoms of Lafora disease: an electroclinical and genetic study in five Apulian (Southern Italy) families. Seizure 2020;83:145-53.** PMID 33152654
- 18
- Dubey D, Ganesh S. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 2008;17:3010-20. PMID 18617530
- 19
- Dubey D, Parihar R, Ganesh S. Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy. Genomics 2012;99:36-43. PMID 22036712
- 20
- Duran J, Gruart A, Garcia-Rocha M, Delgado-Garcia JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum Mol Genet 2014;23(12):3147-56. PMID 24452334
- 21
- Elliot EJ, Talbot IC, Pye IF, Hodges S, Swift PG, Tanner MS. Lafora disease: a progressive myoclonus epilepsy. J Paediatr Child Health 1992;28:455-8. PMID 1466943
- 22
- Ferrari Aggradi CR, Rimoldi M, Romagnoli G, et al. Lafor disease: a case report and evolving treatment advancements. Brain Sci 2023;13(12)1679. PMID 38137127
- 23
- Ferlazzo E, Canafoglia L, Michelucci R, et al. Mild Lafora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 2014;55(12):e129-33. PMID 25270369
- 24
- Fu Y, Zhou C, Song R, et al. A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease. Neurol Sci 2020;41(8):2267-70. PMID 32342326
- 25
- Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet 2002;11(11):1263-71. PMID 12019207
- 26
- Ganesh S, Puri R, Singh S, Mittal S, Dubey D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet 2006;51(1):1-8. PMID 16311711
- 27
- Garcia-Cabrero AM, Marinas A, Guerrero R, de Córdoba SR, Serratosa JM, Sánchez MP. Laforin and malin deletions in mice produce similar neurologic impairments. J Neuropathol Exp Neurol 2012;71(5):413-21. PMID 22487859
- 28
- Genton P. Lafora's disease (EPM2). Rev Neurol (Paris) 2007;163:47-53. PMID 17304172
- 29
- Genton P, Malafosse A, Moulard B, et al. Progressive myoclonus epilepsies. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence, 4th edition. Montrouge, France: John Libbey Eurotext, 2005:441-65.
- 30
- Giraldez BG, Serratosa JM. Lafora disease. In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer, 2010:1231-4.
- 31
- Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav 2016;62:132-5. PMID 27459034
- 32
- Gomez-Abad C, Gomez-Garre P, Gutierrez-Delicado E, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 2005;64(6):982-6. PMID 15781812
- 33
- Gomez-Garre P, Gutierrez-Delicado E, Gomez-Abad C, et al. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora. Neurology 2007;68:1369-73. PMID 17452581
- 34
- Halliday AM. The clinical incidence of myoclonus. In: Williams D, editor. Modern trends in neurology. Vol. 4. London: Butterworths, 1967:69-105.
- 35
- Ianzano L, Zhang J, Chan EM, et al. Lafora progressive myoclonus epilepsy mutation database-EPM2A and NHLRC1 (EMP2B) genes. Hum Mutat 2005;26(4):397. PMID 16134145
- 36
- Jansen AC, Andermann E. Progressive myoclonus epilepsy, Lafora type. In: Gene Reviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1389. Last update 2019.
- 37
- Kaufman MA, Dwork AJ, Willson NJ, John S, Liu JD. Late-onset Lafora's disease with typical intraneuronal inclusions. Neurology 1993;43(6):1246-8. PMID 8170576
- 38
- Kecmanovic M, Keckarevic-Markovic M, Keckarevic D, Stevanovic G, Jovic N, Romac S. Genetics of Lafora progressive myoclonic epilepsy: current perspectives. Appl Clin Genet 2016;9:49-53. PMID 27194917
- 39
- Lafora GR. Uber das Vorkommen amyloider Korperchen im Innern der Ganglienzellen: zugleich en Beitrag zum Studium der amyloiden Substanz im Nervensystem. Virchows Arch Pathol Anat Physiol Klin Med 1911;205:295-303.
- 40
- Lafora GR, Glueck B. Beitrag zur Histopathologie der myoklonischen Epilepsie. Z Gesamte Neurol Psychiatr 1911;6:1-14.
- 41
- Lesca G, Boutry-Kryza N, de Toffol B, et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia 2010;51(9):1691-8. PMID 20738377
- 42
- Lohi H, Turnbull J, Zhao XC, et al. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2007;68:996-1001. PMID 17389303
- 43
- Markussen K, Macedo J, Machio M, et al. The 6th International Lafora Epilepsy Workshop: advances in the search for a cure. Epilepsy Behav 2021;119:107975. PMID 33946009
- 44
- Mikati MA, Tabbara F. Managing Lafora body disease with vagal nerve stimulation. Epileptic Disord 2017;19(1):82-6. PMID 28238966
- 45
- Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 2007;16:753-62. PMID 17337485
- 46
- Molla B, Heredia M, Sanz P. Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model. Mol Neurobiol 2021;58(6):2508-22. PMID 33447969
- 47
- Monaghan TS, Delanty N. Lafora disease: epidemiology, pathophysiology and management. CNS Drugs 2010;24(7):549-61. PMID 20527995
- 48
- Muccioli L, Farolfi A, Pondrelli F, et al. FDG-PET assessment and metabolic patterns in Lafora disease. Eur J Nucl Med Mol Imaging 2020;47(6):1576-84. PMID 31858178
- 49
- Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol 2018;14(10):606-17. PMID 30143794
- 50
- Panayiotopoulos CP. Diseases frequently associated with epileptic seizures. In: Panayiotopoulos CP, editor. A Clinical Guide to Epileptic Syndromes and Their Treatment. Revised 2nd edition. London: Springer, 2010:533-63.
- 51
- Parihar R, Rai A, Ganesh S. Lafora disease: from genotype to phenotype. J Genet 2018;97(3):611-24. PMID 30027899
- 52
- Pederson BA, Turnbull J, Epp JR, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol 2013;74(2):297-300. PMID 23913475
- 53
- Pichiecchio A, Veggiotti P, Cardinali S, Longaretti F, Poloni GU, Uggetti C. Lafora disease: spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol 2008;12(4):342-7. PMID 18063398
- 54
- Ragona F, Canafoglia L, Castellotti B, et al. Early Parkinsonism in a Senegalese girl with Lafora disease. Epileptic Disord 2020;22(2):233-6. PMID 32301727
- 55
- Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE task force on nosology and definitions. Epilepsia 2022;63(6):1443-74. PMID 35503725
- 56
- Riva A, Orsini A, Scala M, et al. Italian cohort of Lafora disease: clinical features, disease evolution, and genotype-phenotype correlations. J Neurol Sci 2021;424:117409.** PMID 33773408
- 57
- Robitaille Y, Carpenter S, Karpati G, DiMauro S. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal aging. Brain 1980;103:315-36. PMID 6249438
- 58
- Rubio T, Campos-Rodriguez A, Sanz P. Beneficial effect of fingolimod in a Lafora disease mouse model by preventing reactive astrogliosis-derived neuroinflammation and brain infiltration of T-lymphocytes. Mol Neurobiol 2024;61(6):3105-20. PMID 37971656
- 59
- Salar S, Yeni N, Gunduz A, et al. Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families. Epilepsy Res 2012;98:273-6. PMID 22047982
- 60
- Serratosa JM, Gomez-Garre P, Gallardo ME, et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 1999;8(2):345-52. PMID 9931343
- 61
- Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005;4(4):239-48. PMID 15778103
- 62
- Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 2009;30(5):715-23. PMID 19267391
- 63
- Singh S, Satishchandra P, Shankar SK, Ganesh S. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 2008;29(6):E1-12. PMID 18311786
- 64
- Tinuper P, Plazzi G, Monari L, et al. Arylsulfatase A pseudodeficiency and Lafora bodies in a patient with progressive myoclonic epilepsy. Epilepsia 1994;35:332-5. PMID 7908874
- 65
- Turnbull J, Kumar S, Ren ZP, et al. Lafora progressive myoclonus epilepsy: disease course homogeneity in a genetic isolate. J Child Neurol 2008;23(2):240-2. PMID 18263761
- 66
- Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Disord 2016;18(S2):38-62. PMID 27702709
- 67
- Turnbull J, Wang P, Girard JM, et al. Glycogen hyperphosphorylation underlies Lafora body formation. Ann Neurol 2010;68(6):925-33. PMID 21077101
- 68
- Villanueva V, Alvarez-Linera J, Gomez-Garre P, Gutierrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia 2006;47:788-92. PMID 16650146
- 69
- Yamanami S, Ishihara T, Takahashi M, Uchino F. Comparative study of intraneuronal polyglucosan bodies in brains from patients with Lafora disease and aged dogs. Acta Pathol Jpn 1992;42:787-92. PMID 1335204
- 70
- Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;46:283-7. PMID 11518630
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Aparna Polavarapu MD
Dr. Polavarapu of Albert Einstein College of Medicine and Montefiore Medical Center has no relevant financial relationships to disclose.
See Profile
Editor
-
Solomon L Moshé MD
Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile
Former Authors
- Frederick Andermann MD
- Andrew N Wilner MD FACP
- Eva Andermann MD PhD
- C P Panayiotopoulos MD PhD
- Maria Machio Castello MD
- Jose M Serratosa MD PhD
Patient Profile
- Age range of presentation
-
- 6 to 44 years
- Sex preponderance
-
- female=male
- Heredity
-
- heredity typical
- autosomal recessive
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Lafora disease: G40.3
- ICD-11
-
- Progressive myoclonic epilepsy: 8A61.41
- OMIM
-
- Myoclonic epilepsy of Lafora: #254780
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Epilepsy & Seizures
Intermittent explosive disorder
Nov. 11, 2024
-
General Neurology
Metal neurotoxicity
Nov. 05, 2024
-
Neurobehavioral & Cognitive Disorders
Vascular cognitive impairment
Oct. 30, 2024
-
Neurobehavioral & Cognitive Disorders
Addictive disorders
Oct. 28, 2024
-
Neurobehavioral & Cognitive Disorders
Automatic-voluntary dissociation
Oct. 27, 2024
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Neurobehavioral & Cognitive Disorders
Pre-mild cognitive impairment
Oct. 15, 2024
